Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (symbol: VTGN) is a pioneering biotechnology firm committed to improving the lives of patients with central nervous system (CNS) disorders. The company leverages its advanced stem cell technology platform, which is based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed human cells. This innovative platform enables the creation of novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue, and cell therapy, providing clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
At the clinical stage, Vistagen is actively involved in developing and commercializing a robust pipeline consisting of six product candidates. Five of these candidates are clinical-stage investigational agents known as pherines, which represent a new class of drugs. Notable products within their portfolio include:
- PH94B: A novel neuroactive nasal spray designed to treat social anxiety disorder.
- PH10: An odorless, fast-acting synthetic neurosteroid aimed at addressing major depressive disorder (MDD).
- AV-101: An oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR), which is being developed to treat MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.
Vistagen's innovative approach and dedication to CNS disorders position it as a significant player in the biotechnology sector. The company is continually making strides in its research and clinical trials, striving to bring groundbreaking therapies to market. Investors and stakeholders can look forward to Vistagen's ongoing developments and potential future successes as it targets unmet medical needs with its cutting-edge technologies and therapeutic candidates.
VistaGen Therapeutics (NASDAQ: VTGN) has received a 180-day extension from Nasdaq to regain compliance with its minimum bid price requirement, now having until April 12, 2021. This extension does not impact the company's current listing status on the Nasdaq Capital Market. CEO Shawn K. Singh expressed optimism about regaining compliance while advancing their three CNS drug candidates aimed at addressing anxiety and depression disorders.
VistaGen Therapeutics (VTGN) announced promising data from its second preclinical study of AV-101 combined with probenecid, which may enhance the treatment of central nervous system (CNS) disorders. The study showed that the combination significantly raised brain levels of AV-101's active metabolite, 7-Cl-KYN, improving its therapeutic potential. AV-101, with an excellent safety profile and no significant side effects, could offer a new treatment option for anxiety and depression. The findings could lead to further clinical development under FDA's Fast Track designation for both major depressive disorder and neuropathic pain.
VistaGen Therapeutics (Nasdaq: VTGN), a biopharmaceutical firm focused on CNS disorders, will present at the LD Micro 500 Virtual Conference from September 1-4, 2020. CEO Shawn Singh will speak on September 3 at 11 a.m. EDT. Investors can watch the live webcast by registering online. VistaGen's pipeline includes three drug candidates targeting anxiety and depression, all showing promising safety profiles. The presentation aims to highlight the company's innovative approach to treating CNS disorders and its position within the micro-cap market.
VistaGen Therapeutics (Nasdaq: VTGN) reported its fiscal 2021 Q1 results, highlighting key advancements in its drug development pipeline. The Company reached an agreement with the FDA on PH94B's Phase 3 study for social anxiety disorder, with enrollment for 182 adults planned. Financially, VistaGen secured a $5 million non-dilutive license payment and completed a public offering, raising approximately $14.29 million. Notably, net loss decreased to $3.5 million, while R&D expenses dropped from $4.3 million to $1.7 million compared to the previous year.
VistaGen Therapeutics (Nasdaq: VTGN) announced that underwriters of its public offering exercised their over-allotment option, bringing additional gross proceeds of approximately $1.79 million. Overall, the offering totaled $14.29 million with 17,868,250 shares issued. The funds will support the development of CNS pipeline programs, general research, and working capital. Maxim Group LLC managed the offering, which was conducted under an effective shelf registration statement with the SEC.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) has closed an underwritten public offering of 15,625,000 shares at $0.80 per share, generating $12.5 million in gross proceeds. The proceeds will support the development of CNS pipeline programs, R&D, and general corporate purposes. An option for underwriters to purchase up to an additional 2,343,750 shares within 45 days is also granted. The offering was conducted under an effective shelf registration statement.
VistaGen Therapeutics (NASDAQ: VTGN) received a $5 million non-dilutive upfront license payment from EverInsight Therapeutics for the development of PH94B, a nasal spray targeting anxiety-related disorders. This collaboration focuses on commercializing PH94B in key Asian markets, including Greater China and Southeast Asia.
VistaGen is eligible for milestone payments and royalties on future sales. The FDA has granted Fast Track designation for PH94B's Phase 3 development as a treatment for social anxiety disorder (SAD), marking it as a potential breakthrough in non-addictive anxiety treatment.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) announced the pricing of a public offering of 15,625,000 shares at $0.80 per share, aiming to raise gross proceeds of approximately $12.5 million. The underwriter has a 45-day option to purchase an additional 2,343,750 shares. The funds will support the development of its central nervous system (CNS) pipeline programs as well as general research and development. This offering is part of an effective shelf registration statement filed with the SEC.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has announced an underwritten public offering of common stock, subject to market conditions. The company aims to utilize the proceeds for the continued development of its central nervous system (CNS) pipeline, general research, working capital, and corporate purposes. Maxim Group LLC serves as the sole book-running manager for the offering. This offering is made under an effective shelf registration statement, and a preliminary prospectus supplement will be filed with the SEC.
VistaGen Therapeutics (VTGN) reported its financial results for the fiscal year ending March 31, 2020. The company experienced a decrease in net loss to $22 million from $25.7 million the previous year, primarily due to lower research and development expenses. VistaGen's cash position stood at $1.4 million, with subsequent proceeds of $3 million after fiscal year-end. The strategic collaboration with EverInsight aims to develop PH94B, a nasal spray for anxiety disorders, with potential payments up to $177 million, enhancing the company's pipeline targeting mental health care.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
What does Vistagen Therapeutics, Inc. specialize in?
What is the company's main technological focus?
What are pherines?
Can you name some of Vistagen Therapeutics' key products?
What is PH94B used for?
What is PH10?
What conditions is AV-101 aimed at treating?
How does Vistagen's stem cell technology benefit drug development?
Is Vistagen Therapeutics currently in the clinical stage?
Where can I find the latest news about Vistagen Therapeutics, Inc.?
